

**TDMS No.** 99023 - 04

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS  
ABRIDGED) (a)**

**Date Report Reqsted:** 07/26/2007

**Test Type:** CHRONIC

beta-Myrcene

**Time Report Reqsted:** 09:29:40

**Route:** GAVAGE

**CAS Number:** 123-35-3

**First Dose M/F:** 04/11/02 / 04/10/02

**Species/Strain:** MICE/B6C3F1

**Lab:** BAT

F1\_M3

**C Number:** C99023

**Lock Date:** 12/22/2004

**Cage Range:** ALL

**Date Range:** ALL

**Reasons For Removal:** ALL

**Removal Date Range:** ALL

**Treatment Groups:** Include ALL

**TDMSE Version:** 1.8.0

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident				3
Moribund Sacrifice	7	6	8	12
Natural Death	8	9	11	14
Survivors				
Natural Death	1			
Terminal Sacrifice	34	35	31	21
Animals Examined Microscopically	50	50	50	50

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)
Gallbladder	(49)	(49)	(49)	(49)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)
Intestine Large, Cecum	(49)	(48)	(49)	(47)
Intestine Small, Duodenum	(49)	(47)	(47)	(48)
Adenoma		1 (2%)		
Intestine Small, Ileum	(49)	(47)	(47)	(47)
Carcinoma		1 (2%)		
Intestine Small, Jejunum	(49)	(47)	(49)	(45)
Liver	(50)	(50)	(50)	(50)
Hemangiosarcoma	5 (10%)	1 (2%)	1 (2%)	
Hemangiosarcoma, Metastatic, Spleen	1 (2%)			
Hemangiosarcoma, Multiple		2 (4%)	1 (2%)	
Hepatoblastoma	4 (8%)	6 (12%)	11 (22%)	1 (2%)
Hepatocellular Adenoma	11 (22%)	10 (20%)	13 (26%)	8 (16%)
Hepatocellular Adenoma, Multiple	15 (30%)	31 (62%)	30 (60%)	10 (20%)
Hepatocellular Carcinoma	13 (26%)	16 (32%)	19 (38%)	9 (18%)
Hepatocellular Carcinoma, Multiple	1 (2%)	4 (8%)	9 (18%)	1 (2%)
Ito Cell Tumor Malignant	2 (4%)			
Mesentery	(4)	(7)	(5)	(3)
Hepatoblastoma, Metastatic, Liver		1 (14%)		
Hepatocellular Carcinoma, Metastatic, Liver			1 (20%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (33%)
Pancreas	(50)	(50)	(50)	(50)
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(49)	(50)
Squamous Cell Carcinoma			1 (2%)	1 (2%)
Squamous Cell Papilloma		2 (4%)	1 (2%)	
Stomach, Glandular	(50)	(50)	(50)	(50)
Tongue	(1)	(0)	(0)	(0)
Squamous Cell Carcinoma	1 (100%)			
Tooth	(38)	(33)	(35)	(13)
Peridental Tissue, Fibrosarcoma		1 (3%)		
<b>CARDIOVASCULAR SYSTEM</b>				
Blood Vessel	(0)	(2)	(1)	(2)
Heart	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(50)	(50)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)
Subcapsular, Adenoma	2 (4%)	4 (8%)		
Adrenal Medulla	(50)	(50)	(50)	(50)
Pheochromocytoma Benign			1 (2%)	
Pheochromocytoma Malignant		1 (2%)		
Islets, Pancreatic	(50)	(50)	(50)	(50)
Adenoma		1 (2%)		
Pituitary Gland	(49)	(49)	(50)	(49)
Pars Intermedia, Adenoma			1 (2%)	
Thyroid Gland	(50)	(50)	(50)	(50)
Follicular Cell, Adenoma		1 (2%)	1 (2%)	
Follicular Cell, Carcinoma	1 (2%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
<b>GENERAL BODY SYSTEM</b>				
None				
<b>GENITAL SYSTEM</b>				
Epididymis	(50)	(50)	(50)	(50)
Hepatoblastoma, Metastatic, Liver		1 (2%)		
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)
Preputial Gland	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			
Prostate	(50)	(50)	(50)	(50)
Seminal Vesicle	(50)	(50)	(50)	(50)
Hepatoblastoma, Metastatic, Liver		1 (2%)		
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)
Testes	(50)	(50)	(50)	(50)
Interstitial Cell, Adenoma		1 (2%)	1 (2%)	
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)		
Hemangiosarcoma, Metastatic, Spleen	1 (2%)			
Lymph Node	(2)	(0)	(5)	(1)
Bronchial, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (50%)			
Bronchial, Hepatocellular Carcinoma, Metastatic, Liver			1 (20%)	
Bronchial, Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (100%)
Mediastinal, Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (100%)
Lymph Node, Mandibular	(49)	(50)	(48)	(49)
Melanoma Malignant, Metastatic, Eye			1 (2%)	
Lymph Node, Mesenteric	(49)	(50)	(47)	(44)
Hepatoblastoma, Metastatic, Liver		1 (2%)		
Pheochromocytoma Malignant,		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Metastatic, Adrenal Medulla				
Spleen	(49)	(50)	(48)	(49)
Hemangiosarcoma	1 (2%)	2 (4%)	2 (4%)	
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				1 (2%)
Thymus	(47)	(47)	(48)	(47)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Hepatoblastoma, Metastatic, Liver		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
<b>INTEGUMENTARY SYSTEM</b>				
Skin	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)			
Squamous Cell Carcinoma			1 (2%)	
Subcutaneous Tissue, Sarcoma	1 (2%)			
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Chondroma		1 (2%)		
Skeletal Muscle	(0)	(2)	(1)	(1)
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Peripheral Nerve	(0)	(0)	(1)	(0)
Spinal Cord	(0)	(0)	(1)	(0)
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	5 (10%)	9 (18%)	6 (12%)	13 (26%)
Alveolar/Bronchiolar Adenoma, Multiple	3 (6%)	4 (8%)	3 (6%)	1 (2%)
Alveolar/Bronchiolar Carcinoma	5 (10%)	5 (10%)	2 (4%)	2 (4%)
Alveolar/Bronchiolar Carcinoma,	1 (2%)	2 (4%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Metastatic, Lung Carcinoma, Metastatic, Harderian Gland Carcinoma, Metastatic, Thyroid Gland Hepatoblastoma, Metastatic, Liver Hepatocellular Carcinoma, Metastatic, Liver Melanoma Malignant, Metastatic, Eye Mediastinum, Hemangiosarcoma Nose Carcinoma, Metastatic, Harderian Gland	1 (2%) 4 (8%) (50)	1 (2%) 8 (16%) (50)	1 (2%) 10 (20%) (50) 1 (2%) (50) 1 (2%)	5 (10%) (50)
<b>SPECIAL SENSES SYSTEM</b>				
Eye Melanoma Malignant Harderian Gland Adenoma Adenoma, Multiple Carcinoma Bilateral, Adenoma	(50) (50) 8 (16%) 1 (2%) 1 (2%)	(50) (50) 8 (16%) 2 (4%) 2 (4%)	(50) 1 (2%) (50) 10 (20%) 2 (4%) 2 (4%)	(50) (50) 6 (12%) 1 (2%)
<b>URINARY SYSTEM</b>				
Kidney Hepatocellular Carcinoma, Metastatic, Liver Renal Tubule, Adenoma Urinary Bladder	(50) 1 (2%) (50)	(50) 1 (2%) (50)	(50) 2 (4%) 1 (2%) (49)	(50) 1 (2%) (49)
<b>SYSTEMIC LESIONS</b>				
Multiple Organs Histiocytic Sarcoma Lymphoma Malignant	*(50) 1 (2%)	*(50) 1 (2%) 1 (2%)	*(50) 3 (6%)	*(50)

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
<b>Tumor Summary for Males</b>				
Total Animals with Primary Neoplasms (b)	43	49	50	29
Total Primary Neoplasms	84	120	123	54
Total Animals with Benign Neoplasms	33	45	44	24
Total Benign Neoplasms	46	76	68	39
Total Animals with Malignant Neoplasms	30	33	41	13
Total Malignant Neoplasms	38	44	55	15
Total Animals with Metastatic Neoplasms	7	12	14	6
Total Metastatic Neoplasms	9	17	22	16
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident		1	1	
Moribund Sacrifice	4	5	6	5
Natural Death	7	10	8	28
Survivors				
Terminal Sacrifice	39	34	35	17
Animals Examined Microscopically	50	50	50	50
<b>ALIMENTARY SYSTEM</b>				
Esophagus	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Uterus			1 (2%)	
Nerve, Schwannoma Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Gallbladder	(47)	(50)	(50)	(49)
Sarcoma, Metastatic, Skin		1 (2%)		
Intestine Large, Cecum	(49)	(50)	(50)	(47)
Intestine Large, Colon	(50)	(50)	(50)	(47)
Intestine Large, Rectum	(50)	(49)	(50)	(49)
Intestine Small, Jejunum	(50)	(48)	(49)	(40)
Carcinoma	1 (2%)			
Sarcoma, Metastatic, Skin			1 (2%)	
Liver	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Uterus			1 (2%)	
Hemangiosarcoma			1 (2%)	
Hemangiosarcoma, Metastatic, Skin	1 (2%)			
Hepatocellular Adenoma	6 (12%)	11 (22%)	6 (12%)	7 (14%)
Hepatocellular Adenoma, Multiple		2 (4%)		
Hepatocellular Carcinoma	1 (2%)	7 (14%)	2 (4%)	1 (2%)
Sarcoma, Metastatic, Skin		1 (2%)		
Mesentery	(15)	(18)	(3)	(0)
Hemangioma	1 (7%)			
Hepatocellular Carcinoma, Metastatic, Liver		1 (6%)		
Sarcoma, Metastatic, Skin		1 (6%)		

a - Number of animals examined microscopically at site and number of animals with lesion



Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Schwannoma Malignant, Metastatic, Uncertain Primary Site		1 (6%)		
Pancreas	(50)	(49)	(50)	(48)
Sarcoma, Metastatic, Skin			1 (2%)	
Schwannoma Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(49)	(50)	(47)
Carcinoma, Metastatic, Uterus			1 (2%)	
Squamous Cell Papilloma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Serosa, Schwannoma Malignant, Metastatic, Uncertain Primary Site		1 (2%)		
Stomach, Glandular	(50)	(50)	(50)	(49)
Tooth	(1)	(3)	(4)	(0)
<b>CARDIOVASCULAR SYSTEM</b>				
Blood Vessel	(2)	(2)	(2)	(1)
Heart	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Uterus			1 (2%)	
Hemangioma			1 (2%)	
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(50)	(50)
Sarcoma, Metastatic, Skin		1 (2%)		
Subcapsular, Adenoma	1 (2%)			
Adrenal Medulla	(50)	(50)	(50)	(50)
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Parathyroid Gland	(47)	(34)	(43)	(44)
Pituitary Gland	(50)	(50)	(50)	(50)
Pars Distalis, Adenoma	1 (2%)	1 (2%)	1 (2%)	
Thyroid Gland	(50)	(50)	(50)	(50)
Follicular Cell, Adenoma	1 (2%)		1 (2%)	
<b>GENERAL BODY SYSTEM</b>				
None				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
<b>GENITAL SYSTEM</b>				
Clitoral Gland	(49)	(48)	(50)	(49)
Hemangiosarcoma		1 (2%)		
Ovary	(50)	(50)	(49)	(49)
Carcinoma, Metastatic, Uterus			1 (2%)	
Cystadenoma	2 (4%)	1 (2%)		
Granulosa-Theca Tumor Benign				1 (2%)
Luteoma	1 (2%)		1 (2%)	
Oviduct	(0)	(0)	(1)	(0)
Uterus	(50)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)		
Polyp Stromal		1 (2%)	1 (2%)	1 (2%)
Endometrium, Carcinoma			1 (2%)	
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(49)	(49)	(50)
Hemangiosarcoma		1 (2%)		
Hemangiosarcoma, Metastatic, Skin	1 (2%)			
Sarcoma, Metastatic, Skin		1 (2%)		
Lymph Node	(7)	(8)	(7)	(0)
Bronchial, Alveolar/Bronchiolar		1 (13%)		
Carcinoma, Metastatic, Lung				
Bronchial, Sarcoma, Metastatic, Skin		1 (13%)		
Mediastinal, Alveolar/Bronchiolar		1 (13%)		
Carcinoma, Metastatic, Lung				
Mediastinal, Carcinoma, Metastatic,			1 (14%)	
Uterus				
Mediastinal, Fibrosarcoma, Metastatic,			1 (14%)	
Skin				
Mediastinal, Hepatocellular Carcinoma,		1 (13%)		
Metastatic, Liver				
Mediastinal, Sarcoma, Metastatic, Skin		1 (13%)		
Pancreatic, Carcinoma, Metastatic,			1 (14%)	
Uterus				
Lymph Node, Mandibular	(50)	(50)	(49)	(49)
Lymph Node, Mesenteric	(47)	(48)	(44)	(39)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Sarcoma, Metastatic, Skin		1 (2%)		
Spleen	(49)	(50)	(50)	(50)
Hemangiosarcoma, Metastatic, Skin	1 (2%)			
Thymus	(49)	(48)	(47)	(48)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Hemangioma			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Sarcoma, Metastatic, Skin		2 (4%)		
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(50)	(50)	(50)	(50)
Skin	(50)	(50)	(50)	(50)
Basosquamous Tumor Benign	1 (2%)			
Subcutaneous Tissue, Fibroma	1 (2%)			
Subcutaneous Tissue, Fibrosarcoma	1 (2%)		1 (2%)	1 (2%)
Subcutaneous Tissue, Hemangioma	1 (2%)			
Subcutaneous Tissue, Hemangiosarcoma	1 (2%)			
Subcutaneous Tissue, Sarcoma	1 (2%)	4 (8%)	1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Skeletal Muscle	(0)	(3)	(0)	(0)
Sarcoma, Metastatic, Skin		1 (33%)		
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(50)
Peripheral Nerve	(0)	(1)	(0)	(0)
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	4 (8%)	1 (2%)	5 (10%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
Alveolar/Bronchiolar Adenoma, Multiple				2 (4%)
Alveolar/Bronchiolar Carcinoma	2 (4%)	1 (2%)	1 (2%)	
Carcinoma, Metastatic, Uterus			1 (2%)	
Fibrosarcoma, Metastatic, Skin			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver		2 (4%)	1 (2%)	
Sarcoma, Metastatic, Skin		2 (4%)		
Sarcoma, Metastatic, Uncertain Primary Site		1 (2%)		
Mediastinum, Fibrosarcoma, Metastatic, Skin			1 (2%)	
Nose	(50)	(50)	(50)	(50)
Trachea	(50)	(50)	(50)	(50)
<b>SPECIAL SENSES SYSTEM</b>				
Ear	(0)	(0)	(1)	(0)
Eye	(50)	(50)	(50)	(49)
Harderian Gland	(50)	(50)	(50)	(49)
Adenoma	4 (8%)	6 (12%)	5 (10%)	5 (10%)
Carcinoma			1 (2%)	
Bilateral, Adenoma		1 (2%)		
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Uterus			1 (2%)	
Ureter	(0)	(0)	(1)	(0)
Urinary Bladder	(50)	(50)	(50)	(49)
Carcinoma, Metastatic, Uterus			1 (2%)	
<b>SYSTEMIC LESIONS</b>				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma			2 (4%)	1 (2%)
Lymphoma Malignant	7 (14%)	6 (12%)	3 (6%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

beta-Myrcene

Time Report Requested: 09:29:40

Route: GAVAGE

CAS Number: 123-35-3

First Dose M/F: 04/11/02 / 04/10/02

Species/Strain: MICE/B6C3F1

Lab: BAT

---

B6C3F1 MICE FEMALE	0 G/KG	0.25 G/KG	0.5 G/KG	1.0 G/KG
--------------------	--------	-----------	----------	----------

---

**Tumor Summary for Females**

<b>Total Animals with Primary Neoplasms (b)</b>	30	28	27	21
<b>Total Primary Neoplasms</b>	39	46	36	24
<b>Total Animals with Benign Neoplasms</b>	21	19	20	18
<b>Total Benign Neoplasms</b>	25	25	23	20
<b>Total Animals with Malignant Neoplasms</b>	14	18	12	4
<b>Total Malignant Neoplasms</b>	14	21	13	4
<b>Total Animals with Metastatic Neoplasms</b>	1	7	4	
<b>Total Metastatic Neoplasms</b>	3	27	16	
<b>Total Animals with Malignant Neoplasms Uncertain Primary Site</b>		2		
<b>Total Animals with Neoplasms Uncertain-Benign or Malignant</b>				
<b>Total Uncertain Neoplasms</b>				

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors